YTS 109
Alternative Names: YTS-109Latest Information Update: 26 May 2025
At a glance
- Originator China Immunotech
- Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Systemic lupus erythematosus
- Clinical Phase Unknown Autoimmune disorders
Most Recent Events
- 19 May 2025 China Immunotech plans a phase I trial for Autoimmune disorders (Parentral) in May 2025 (NCT06978647)
- 25 Apr 2025 China Immunotech plans a phase 0 trial for Systemic Lupus Erythematosus (Treatment-experienced) in April 2025 (Parenteral, Injection) (NCT06943937)
- 16 Apr 2025 Phase-I clinical trials in Systemic lupus erythematosus in China (Parenteral) (NCT06943937)